José Baselga
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
Di Cosimo S, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, de Braud F, Iorio M, Verderio P, Untch M, de Azambuja E, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers F, Daidone M. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. Int J Mol Sci 2020; 21
Feb 18, 2020Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
Feb 18, 2020Int J Mol Sci 2020; 21
Di Cosimo Serena, Pusztai Lajos, Pritchard Kathleen, Nuciforo Paolo, Vincent-Salomon Anne, Symmans Fraser, Apolone Giovanni, de Braud Filippo G, Iorio Marilena V, Verderio Paolo, Untch Michael, de Azambuja Evandro, Appierto Valentina, Pizzamiglio Sara, Silvestri Marco, Baselga José, Piccart Martine, Huober Jens, Izquierdo Miguel, de la Pena Lorena, Hilbers Florentine S, Daidone Maria Grazia
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Huober J, Hackman J, Dasappa L, Ciruelos E, Toral Pena J, Adamchuk H, Hickish T, de la Pena L, Jackisch C, Gelber R, Piccart-Gebhart M, Jouannaud C, Wildiers H, Lecocq C, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D, Sarp S, Láng I, Smith I, Boyle F, Xu B, Di Cosimo S. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019; 118:169-177.
Aug 1, 2019Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
Aug 1, 2019Eur J Cancer 2019; 118:169-177
Huober Jens, Hackman John, Dasappa Lokanatha, Ciruelos Eva, Toral Pena Juan Carlos, Adamchuk Hryhoriy, Hickish Tamas, de la Pena Lorena, Jackisch Christian, Gelber Richard D, Piccart-Gebhart Martine, Jouannaud Christelle, Wildiers Hans, Lecocq Christophe, Holmes Eileen, Baselga José, de Azambuja Evandro, Untch Michael, Fumagalli Debora, Sarp Severine, Láng István, Smith Ian, Boyle Frances, Xu Binghe, Di Cosimo Serena
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
Di Cosimo S, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud F, Apolone G, Verderio P, Huober J, Daidone M, Peña L, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Tagliabue E. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. Eur J Cancer 2019; 118:1-9.
Jul 5, 2019The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
Jul 5, 2019Eur J Cancer 2019; 118:1-9
Di Cosimo Serena, Gori Stefania, Cinieri Saverio, Torri Valter, Baselga José, Piccart Martine, de Braud Filippo G, Apolone Giovanni, Verderio Paolo, Huober Jens, Daidone Maria Grazia, Peña Lorena de la, Triulzi Tiziana, Pizzamiglio Sara, De Cecco Loris, de Azambuja Evandro, Fumagalli Debora, Putzai Lajos, Harbeck Nadia, Izquierdo Miguel, Tagliabue Elda
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Rothé F, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson S, Chia S, Rosa D, Di Cosimo S, Silva M, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Ignatiadis M. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clin Cancer Res 2019; 25:3581-3588.
Mar 12, 2019Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Mar 12, 2019Clin Cancer Res 2019; 25:3581-3588
Rothé Françoise, Wardley Andrew, Ueno Takayuki, Janni Wolfgang, Huober Jens, Baselga José, Piccart Martine, Loi Sherene, Sotiriou Christos, Dawson Sarah-Jane, Chia Stephen, Rosa Daniela, Di Cosimo Serena, Silva Maria Joao, Venet David, Campbell Christine, Bradburry Ian, Rouas Ghizlane, de Azambuja Evandro, Maetens Marion, Fumagalli Debora, Rodrik-Outmezguine Vanessa, Ignatiadis Michail
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Di Cosimo S, Verderio P, Apolone G, de Braud F, Piccart M, Baselga J, Huober J, Izquierdo M, de la Pena L, de Azambuja E, Hilbers F, Iorio M, Tiberio P, Pizzamiglio S, Appierto V, Daidone M. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. Clin Cancer Res 2019; 25:3887-3895.
Feb 27, 2019Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Feb 27, 2019Clin Cancer Res 2019; 25:3887-3895
Di Cosimo Serena, Verderio Paolo, Apolone Giovanni, de Braud Filippo G, Piccart Martine, Baselga José, Huober Jens, Izquierdo Miguel, de la Pena Lorena, de Azambuja Evandro, Hilbers Florentine, Iorio Marilena V, Tiberio Paola, Pizzamiglio Sara, Appierto Valentina, Daidone Maria Grazia
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Hanker A, Castellino S, Joensuu H, Huober J, Brase J, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Groseclose M, Becker J, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, Langley E, Singh S, Kim P, Frampton G, Sanford E, Owens P, Arteaga C. Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2019; 25:1434.
Feb 15, 2019Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Feb 15, 2019Clin Cancer Res 2019; 25:1434
Hanker Ariella B, Castellino Stephen, Joensuu Heikki, Huober Jens, Brase Jan C, Majjaj Samira, Brohée Sylvain, Venet David, Brown David, Baselga José, Piccart Martine, Sotiriou Christos, Groseclose M Reid, Becker Jennifer, Garrett Joan T, Estrada Mónica Valeria, Moore Preston D, Ericsson Paula González, Koch James P, Langley Emma, Singh Sharat, Kim Phillip S, Frampton Garrett M, Sanford Eric, Owens Philip, Arteaga Carlos L
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Powles R, Pusztai L, Elemento O, Piccart-Gebhart M, Baselga J, Huober J, Di Cosimo S, Sarp S, de Azambuja E, Harbeck N, Nuciforo P, Fumagalli D, Loi S, Sotiriou C, Redmond D, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2018; 4:e181564.
Nov 8, 2018Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Nov 8, 2018JAMA Oncol 2018; 4:e181564
Powles Ryan L, Pusztai Lajos, Elemento Olivier, Piccart-Gebhart Martine, Baselga José, Huober Jens, Di Cosimo Serena, Sarp Severine, de Azambuja Evandro, Harbeck Nadia, Nuciforo Paolo, Fumagalli Debora, Loi Sherene, Sotiriou Christos, Redmond David, Hatzis Christos
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
Lambertini M, de Azambuja E, Gelber R, Piccart-Gebhart M, Moreno-Aspitia A, Baselga J, Huober J, Tenglin R, Di Cosimo S, Azim H, Korde L, Schuehly U, Hilbers F, Guillaume S, Campbell C, Martel S, Ignatiadis M. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer 2018; 125:307-316.
Oct 18, 2018Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
Oct 18, 2018Cancer 2018; 125:307-316
Lambertini Matteo, de Azambuja Evandro, Gelber Richard D, Piccart-Gebhart Martine, Moreno-Aspitia Alvaro, Baselga José, Huober Jens, Tenglin Richard C, Di Cosimo Serena, Azim Hatem A, Korde Larissa, Schuehly Uwe, Hilbers Florentine S, Guillaume Sébastien, Campbell Christine, Martel Samuel, Ignatiadis Michail
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Ponde N, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im Y, Borrego M, Chen D, Rodeheffer R, Piccart M, Suter T, Bozovic-Spasojevic I, Fumagalli D, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, de Azambuja E. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat 2017; 168:631-638.
Dec 27, 2017Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Dec 27, 2017Breast Cancer Res Treat 2017; 168:631-638
Ponde Noam, Maetens Marion, Harbeck Nadia, Pusztai Lajos, Berghorn Michael, Im Young-Hyuck, Borrego Manuel Ruiz, Chen Dar-Ren, Rodeheffer Richard, Piccart Martine, Suter Thomas, Bozovic-Spasojevic Ivana, Fumagalli Debora, Bradbury Ian, Lambertini Matteo, Ewer Michael, Campbell Christine, Ameels Helene, Zardavas Dimitrios, Di Cosimo Serena, Baselga José, Huober Jens, Izquierdo Miguel, de Azambuja Evandro
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Hanker A, Castellino S, Joensuu H, Huober J, Brase J, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Groseclose M, Becker J, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, Langley E, Singh S, Kim P, Frampton G, Sanford E, Owens P, Arteaga C. HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 2017; 23:4323-4334.
Apr 5, 2017HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Apr 5, 2017Clin Cancer Res 2017; 23:4323-4334
Hanker Ariella B, Castellino Stephen, Joensuu Heikki, Huober Jens, Brase Jan C, Majjaj Samira, Brohée Sylvain, Venet David, Brown David, Baselga José, Piccart Martine, Sotiriou Christos, Groseclose M Reid, Becker Jennifer, Garrett Joan T, Estrada Mónica Valeria, Moore Preston D, Ericsson Paula González, Koch James P, Langley Emma, Singh Sharat, Kim Phillip S, Frampton Garrett M, Sanford Eric, Owens Philip, Arteaga Carlos L
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Fumagalli D, Di Cosimo S, de Azambuja E, de la Pena L, Nuciforo P, Brase J, Huober J, Baselga J, Piccart M, Loi S, Coccia-Portugal M, Chang T, Gomez H, Venet D, Ignatiadis M, Azim H, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Sotiriou C. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2017; 3:227-234.
Feb 1, 2017RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Feb 1, 2017JAMA Oncol 2017; 3:227-234
Fumagalli Debora, Di Cosimo Serena, de Azambuja Evandro, de la Pena Lorena, Nuciforo Paolo, Brase Jan C, Huober Jens, Baselga José, Piccart Martine, Loi Sherene, Coccia-Portugal Maria Antonia, Chang Tsai-Wang, Gomez Henry, Venet David, Ignatiadis Michail, Azim Hatem A, Maetens Marion, Rothé Françoise, Salgado Roberto, Bradbury Ian, Pusztai Lajos, Harbeck Nadia, Sotiriou Christos
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Baselga J, de Haas S, Olsen S, Samant M, Guardino A, Huober J, Ro J, Verma S, Lewis Phillips G, Pegram M. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clin Cancer Res 2016; 22:3755-63.
Feb 26, 2016Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Feb 26, 2016Clin Cancer Res 2016; 22:3755-63
Baselga José, de Haas Sanne L, Olsen Steve, Samant Meghna K, Guardino Alice E, Huober Jens, Ro Jungsil, Verma Sunil, Lewis Phillips Gail D, Pegram Mark D